Biopharma Schizophrenia: High Demand For Innovation Vs. Pleas For 'Me-Too' Drugs

So, let’s not denigrate new drugs that are not first-in-class upon FDA approval. These can be valuable new medicines whose true value will be determined only after significant use in patients.